Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce
D S
DS
University of Chicago, Section of Transplantation Surgery, IL 60637, USA.
Newell
K A
KA
Woodle
E S
ES
Millis
J M
JM
Piper
J B
JB
Huss
E
E
Thistlethwaite
J R
JR
D000328:Adult; D000704:Analysis of Variance; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone